Research Purposes Only. NOT FOR HUMAN CONSUMPTION
Simple clean guide – FDA-approved MS peptide/protein medications plus non-FDA-approved experimental peptides
people discuss for MS-related symptoms.
Important: This is educational only. MS treatment should be managed by a neurologist. Do not replace disease-modifying
therapy, steroids for relapse care, or prescribed medicines with research peptides. Non-FDA-approved peptides have uncertain
purity, dosing, long-term safety, and benefit
The dose ranges below are label dosing for FDA-approved MS medicines or commonly discussed clinical/research-style
ranges for non-FDA-approved peptides. They are not personal prescriptions. MS symptoms can come from active
inflammation, relapse, infection, medication effects, heat, sleep issues, anemia, thyroid disease, B12 deficiency, or disease
progression, so dosing decisions need medical supervisio
| Option | FDA Status / Role in MS | Typical Label Dosing | Notes |
|---|---|---|---|
| Glatiramer acetate (Copaxone, Glatopa) | FDA-approved disease-modifying therapy for relapsing forms of MS | 20 mg subQ once daily or 40 mg subQ three times weekly | Synthetic polypeptide. Reduces relapses; not for immediate symptom relief. Rare anaphylaxis warning. |
| Interferon beta-1a IM (Avonex) | FDA-approved disease-modifying therapy for relapsing forms of MS | 30 mcg IM once weekly | Protein biologic. May cause flu-like symptoms, liver issues, mood effects; labs monitored. |
| Interferon beta-1a SC (Rebif) | FDA-approved disease-modifying therapy for relapsing forms of MS | 22 mcg or 44 mcg subQ three times weekly | Titration helps reduce flu-like symptoms. Labs monitored. |
| Interferon beta-1b (Betaseron, Extavia) | FDA-approved disease-modifying therapy for relapsing forms of MS | Titrated to 0.25 mg subQ every other day | Injection reactions, flu-like symptoms, mood and liver monitoring needed. |
| Peginterferon beta-1a (Plegridy) | FDA-approved disease-modifying therapy for relapsing forms of MS | Titrated to 125 mcg SC or IM every 14 days | Longer-acting interferon option. |
| Repository corticotropin injection (ACTH gel: Acthar/Cortrophin) | FDA-approved for acute MS relapses (not maintenance therapy) | 80–120 units IM or subQ daily for 2–3 weeks | Used when steroids not tolerated. May increase blood pressure, glucose, adrenal suppression risk. |
None of the peptides below are FDA-approved to treat MS. Evidence ranges from mechanistic theory and animal data to limited
human use in other conditions. They should be considered experimental.
| Peptide | Possible Symptom Target | Commonly Discussed Dosage Range | Evidence / Caution |
|---|---|---|---|
| Thymosin alpha-1 (TA1) | Immune modulation, inflammation balance, relapse-risk theory | 1.6 mg subQ 2x/week; sometimes 2–3x/week | Not FDA-approved for MS. Use caution with autoimmune modulation stacking. |
| Thymosin beta-4 / TB-500 | Tissue repair, inflammation, theoretical myelin support | 2–5 mg weekly (split doses for 4–6 weeks, then maintenance) | Mainly animal data; no human MS proof. Avoid with active cancer concerns. |
| BPC-157 | Inflammation, gut-brain axis, injury recovery theory | 250–500 mcg daily subQ (sometimes split) | Investigational; no MS-specific clinical proof. |
| KPV | Systemic/gut inflammation, cytokine modulation | 200–500 mcg daily (oral or subQ) | Not FDA-approved; human MS data lacking. Possible GI or injection irritation. |
| Semax | Brain fog, focus, fatigue, neuroprotection theory | 300–600 mcg intranasal daily (10–20 day cycles) | Not FDA-approved (U.S.); limited MS evidence. May cause headache/insomnia. |
| Selank | Anxiety, stress, sleep, neuroimmune theory | 250–500 mcg intranasal daily (cycled use) | Limited MS evidence. Watch mood or sedation changes. |
| MOTS-c | Fatigue, mitochondrial energy, exercise tolerance | 5–10 mg subQ 1–3x/week | Experimental; no MS efficacy proof. Avoid in uncontrolled metabolic issues. |
| GHK-Cu | Skin, hair, wound healing (not MS-specific) | 1–2 mg subQ 2–5x/week or topical | Not MS-targeted. Copper irritation possible. |
| LL-37 | Immune/antimicrobial peptide | No reliable MS dosing | Can be pro-inflammatory; generally avoided for MS use. |
| VIP (vasoactive intestinal peptide) | Neuroimmune and anti-inflammatory theory | No standard dosing; varies widely | May lower BP, cause flushing/headache. Not FDA-approved for MS. |
| ARA-290 / cibinetide | Neuropathic pain, nerve protection | No standard MS dosing | Investigational; not proven for MS treatment. |
| MS Symptom / Goal | Most Relevant Peptide Categories | Notes |
|---|---|---|
| Relapse prevention / disease modification | FDA DMTs: glatiramer acetate, interferon beta products | Proven MS medications requiring neurologist supervision. |
| Acute relapse recovery | ACTH gel; high-dose corticosteroids (non-peptide standard care) | Used short-term for relapses only, not long-term maintenance. |
| Inflammation / autoimmune balance | TA1, KPV, TB-4 / TB-500, BPC-157 | Experimental in MS; use only under clinician supervision, especially with DMTs. |
| Brain fog / cognition / fatigue | Semax, MOTS-c; Selank (if anxiety worsens cognition) | Rule out underlying causes like B12 deficiency, thyroid issues, anemia, or sleep disorders. |
| Nerve pain | ARA-290 / cibinetide (theory), Selank, BPC-157, TB-500 | Standard treatments like gabapentin, pregabalin, duloxetine are commonly required. |
| Repair / recovery / mobility support | TB-4 / TB-500, BPC-157, MOTS-c | No peptide proven to remyelinate MS lesions in humans; physical therapy remains essential. |
Avoid self-starting experimental peptides if pregnant or trying to conceive, actively infected, immunocompromised, on
chemotherapy/biologics without physician review, history of cancer, uncontrolled heart rhythm issues, uncontrolled blood
pressure/glucose, severe liver/kidney disease, or active relapse symptoms without neurologic evaluation
